Table 1 Demographic data
|  | Total (n = 66) | ASDAS-CRP< 2.1 (n = 37) | ASDAS-CRP ≥ 2.1 (n = 29) | P-value |
|---|---|---|---|---|
Age, years, mean (SD) | 49.3 (13.5) | 49.08 (14.01) | 49.65 (13.13) | 0.868 |
Male sex, n (%) | 41 (62.1) | 22 (59.46) | 19 (65.52) | 0.615 |
BMI, mean (SD)  - BMI < 30, n (%) *  - BMI ≥ 30, n (%) | 25.9 (6.2) 54 (81.8) 12 (18.2) | 24.7 (3.57) 34 (91.9) 3 (8.1) | 27.5 (8.21) 20 (66.7) 9 (31.3) | 0.060 0.017 |
HLA-B27 positivity, n (%) | 44 | 23 (62.16) | 21 (72.41) | 0.381 |
Radiographic change, n (%) | 48 | 25 (67.57) | 23 (79.31) | 0.288 |
Smoking, n (%) | 10 | 4 (10.8) | 6 (20.69) | 0.315 |
Previous duration of diagnosis before enrollment, years, median (IQR) | 8 (4–12) | 8 (3–10) | 9 (4–15) | 0.164 |
Duration of symptoms prior to treatment, years, mean (SD)*  - ≤ 2 years, n (%)  - > 2 years, n (%) | 1.2 (1.2) 43 (65.2) 23 (34.8) | 0.9 (1.1) 29 (78.4) 8 (21.6) | 1.6 (1.3) 14 (48.3) 15 (51.7) | 0.034 0.011 |
Peripheral joint involvement, n (%)  - TJC-28, mean (SD)  - SJC-28, mean (SD) | 25 (37.9) 0.4 (1.8) 0.3 (1.6) | 12 (32.4) 0.1 (0.3) 0 | 13 (44.8) 0.8 (2.7) 0.7 (2.5) | 0.303 0.020 0.009 |
Enthesitis, n (%) | 36 (54.5) | 19 (51.4) | 17 (58.6) | 0.556 |
Previous uveitis, n (%) | 25 (37.9) | 13 (35.1) | 12 (41.4) | 0.604 |
Syndesmophyte presence, n (%)* | 30 (45.5) | 11 (29.7) | 19 (65.5) | 0.004 |
The highest grade of sacroiliitis, median (IQR) | 3 (2–4) | 3 (2–3) | 3 (2–4) | 0.155 |
Psoriasis, n (%) Nail abnormalities, n (%) | 12 (18.2) 11 (16.7) | 8 (21.6) 7 (19.0) | 4 (13.8) 4 (13.8) | 0.413 0.743 |
Inflammatory bowel disease (%) | 1 (1.5) | 0 | 1 (3.45) | 0.439 |
WBC (x 10^3 cumm), mean (SD)* | 7.0 (2.1) | 6.1 (1.6) | 8.2 (2.1) | < 0.001 |
Lymphocyte count (x 10^3 cumm), mean (SD) | 2.0 (0.8) | 2.0 (0.9) | 2.1 (0.9) | 0.661 |
Hemoglobin (g/dL), mean (SD) | 12.7 (1.9) | 12.9 (1.8) | 12.4 (2.0) | 0.274 |
Platelet count (x 10^3 cumm), mean (SD) | 280 (73) | 268 (75) | 294 (70) | 0.164 |
ESR (mm/Hg), median (IQR)* | 28 (15–49) | 23 (7–38) | 41 (24–67) | 0.002 |
CRP (mg/dL), median (IQR)* | 2.5 (0-14.1) | 1.5 (0-2.4) | 16.2 (7.2–28.9) | < 0.001 |
Concurrent Medication usage, n (%)  - NSAIDS  - MTX*  - SSZ  - LEF  - Glucocorticoid* Biologic usage, n (%)  - Anti TNF  -Secukinumab | 44 (66.7) 34 (51.5) 56 (84.8) 16 (24.2) 7 (10.6) 16 (24.2) 11 (16.7) 5 (7.6) | 20 (54.1) 15 (40.5) 30 (81.1) 6 (16.2) 1 (2.7) 12 (32.4) 9 (24.3) 3 (8.1) | 22 (75.9) 19 (65.5) 26 (84.9) 10 (34.5) 6 (20.7) 4 (13.79) 2 (6.9) 2 (6.9) | 0.068 0.044 0.493 0.086 0.038 0.079 0.095 1.000 |